Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2005 Dec 7;17(2):99–106. doi: 10.1002/jmv.1890170202

Tolerance of one‐month intranasal interferon

G M Scott 1,✉, J K Onwubalili 1, J A Robinson 1, C Doré 2, D S Secher 3, K Cantell 4
PMCID: PMC7166573  PMID: 2997387

Abstract

Under double‐blind conditions, groups of volunteers (68 in total) were allocated at random to take intranasal solutions of placebo or one of three doses of highly purified leucocyte interferon by intranasal spray twice a day for 28 days. The highest dose would have been expected to protect against experimental colds. Treatment was discontinued because of upper respiratory symptoms as often in each of the interferon groups as in the placebo group. However, it was possible to distinguish clinically between “colds” on placebo and low‐dose interferon and “reactions to treatment” on high‐dose interferon. The features of the reactions to treatment were a protracted build‐up of local symptoms and minor epistaxis. None of the volunteers on the high‐dose interferon were thought to have a definite cold, but viruses were isolated from four out of six volunteers on low‐dose interferon who had definite colds. Previous experiments had also shown this dose to be insufficient to protect against experimental rhinovirus challenge.

The dose of interferon that appeared to protect against virus infection caused significant unwanted effects. It is essential to find interferon preparations with less inflammatory activity before interferon can be considered for use as a long‐term prophylactic against the common cold.

Keywords: rhinovirus, coronavirus, paramyxovirus, volunteers, leucocyte interferon

References

  1. Beare AS, Reed SE (1977): The study of antiviral compounds in volunteers In Oxford J. (ed): “Chemoprophylaxis and Viral Infection of the Respiratory Tract.” Cleveland: CRC Press, pp 27–55 [Google Scholar]
  2. Betts RF, Erb S, Roth F, Reichman RC, Treanor J, Beutner K, Dolin R (1983): A field trial of intranasal interferon. Proceedings of the International Congress of Chemotherapy, Vienna, Tom 6, SE4. 7, pp 1–5.
  3. Cantell K, Hirvonen S, Kauppinen H‐L, Myllyla G (1981): Production of interferon from human leukocytes from normal donors with the used of Sendai virus. Methods in Enzymology 78: 29–38. [DOI] [PubMed] [Google Scholar]
  4. Farr B, Gwaltney JM, Adams KF, Hayden FG (1983): Intranasal interferon‐alpha2 for prevention of natural rhinovirus colds. Antimicrobial Agents and Chemotherapy 26: 31–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hayden FG, Mills SE, Johns ME (1983): Human tolerance and histopathologic effects of long‐term administration of intranasal interferon‐alpha2 . Journal of Infectious Diseases 148: 914–921. [DOI] [PubMed] [Google Scholar]
  6. Herzog Ch, Just M, Berger R, Havas L, Fernex M (1983): Intranasal interferon for contact prophylaxis against common cold in families. Lancet ii: 962. [DOI] [PubMed] [Google Scholar]
  7. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DAJ (1983): Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrobial Agents and Chemotherapy 24: 713–715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Merigan TC, Reed SE, Hall T, Tyrrell DAJ (1973): Inhibition of respiratory virus infection by locally applied interferon. Lancet i: 563–567. [DOI] [PubMed] [Google Scholar]
  9. Phillpotts RJ, Scott GM, Higgins PG, Wallace J, Tyrrell DAJ, Gauci CL (1983): An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of Hu 1FNalpha2 . Antiviral Research 3: 121–136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Priestman TJ (1980): Initial evaluation of human lymphoblastoid interferon in patients with advanced mallgnant disease. Lancet ii: 113–118. [DOI] [PubMed] [Google Scholar]
  11. Scott GM (1982): Interferon: Pharmacokinetics and toxicity. Proceedings of the Royal Society of London B299, pp 91–107. [DOI] [PubMed]
  12. Scott GM, Secher DS, Flowers D, Bate J, Cantell K, Tyrrell D (1981): Toxicity of Interferon. British Medical Journal 282: 1345–1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Scott GM, Phillpotts RJ, Wallace J, Secher DS, Cantell K, Tyrrell DAJ (1982): Purified interferon as protection against rhinovirus infection. British Medical Journal 284: 1822–1825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Secher DS (1981): Immunoradiometric assay of human leukocyte interferon using monoclonal antibody. Nature 290: 501–502. [DOI] [PubMed] [Google Scholar]
  15. Secher DS, Burke DC (1980): A monoclonal antibody for large‐scale purification of human leukocyte interferon. Nature 285: 446–450. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Virology are provided here courtesy of Wiley

RESOURCES